Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Sell
37
BLTE Quote, Financials, Valuation and Earnings
Last price:
$61.97
Seasonality move
:
-7.4%
Day range:
$61.47 - $63.00
52-week range:
$31.01 - $86.53
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
17.06x
Volume:
35.2K
Avg. volume:
68.8K
1-year change:
39.11%
Market cap:
$1.9B
Revenue:
--
EPS (TTM):
-$1.10
Analysts' Opinion
-
Consensus RatingBelite Bio has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Belite Bio has an estimated upside of 27.82% from its current price of $62.00.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $62.00.
Fair Value
-
According to the consensus of 0 analysts, Belite Bio has 27.82% upside to fair value with a price target of -- per share.
BLTE vs. S&P 500
-
Over the past 5 trading days, Belite Bio has underperformed the S&P 500 by -4.5% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Belite Bio does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Belite Bio has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Belite Bio reported revenues of --.
Earnings Growth
-
Belite Bio has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Belite Bio reported earnings per share of -$0.28.
Enterprise value:
1.9B
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
--
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -$31.4M | -$35.5M | -$11M | -$9.7M | |
| EBITDA | -- | -$31.2M | -$35.4M | -$11M | -$9.7M | |
| Diluted EPS | -- | -$1.30 | -$1.10 | -$0.40 | -$0.28 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | -- | $56.1M | $111.3M | |
| Total Assets | -- | -- | -- | $57.6M | $115.8M | |
| Current Liabilities | -- | -- | -- | -- | -- | |
| Total Liabilities | -- | -- | -- | $4.8M | $3.6M | |
| Total Equity | -- | -- | -- | $52.8M | $112.2M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-27 | 2023-12-27 | 2023-12-27 | |||
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -- | -- | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | -- | -- | -- | -- | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
BLTE
Sector
Market Cap
$1.9B
$46.1M
Price % of 52-Week High
71.65%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
39.11%
-30.52%
Beta (5-Year)
--
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$62.94
200-day SMA
Buy
Level
$51.67
Bollinger Bands (100)
Buy
Level
47.43 - 70.75
Chaikin Money Flow
Buy
Level
7.4M
20-day SMA
Sell
Level
$64.58
Relative Strength Index (RSI14)
Sell
Level
41.02
ADX Line
Buy
Level
16.53
Williams %R
Buy
Level
-88.1446
50-day SMA
Sell
Level
$68.90
MACD (12, 26)
Sell
Level
-2.16
25-day Aroon Oscillator
Sell
Level
-72
On Balance Volume
Neutral
Level
17.8M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
Stock Forecast FAQ
In the current month, BLTE has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BLTE average analyst price target in the past 3 months is --.
-
Where Will Belite Bio Stock Be In 1 Year?
According to analysts, the consensus estimate is that Belite Bio share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Belite Bio?
Analysts are divided on their view about Belite Bio share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Belite Bio is a Sell and believe this share price will drop from its current level to --.
-
What Is Belite Bio's Price Target?
The price target for Belite Bio over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BLTE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Belite Bio is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of BLTE?
You can purchase shares of Belite Bio via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Belite Bio shares.
-
What Is The Belite Bio Share Price Today?
Belite Bio was last trading at $61.97 per share. This represents the most recent stock quote for Belite Bio. Yesterday, Belite Bio closed at $62.00 per share.
-
How To Buy Belite Bio Stock Online?
In order to purchase Belite Bio stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
60
QMCO alert for Dec 26
Quantum [QMCO] is up 49.62% over the past day.
Buy
53
ARQQ alert for Dec 26
Arqit Quantum [ARQQ] is up 49.85% over the past day.
Buy
65
TSLL alert for Dec 26
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 3.73% over the past day.
